Home » Companies » Pharmaceutical in Czechia » Novartis Czech Republic

Novartis Czech Republic

Novartis Czech Republic's Cash & Cash Equivalents fell 100% yoy to CZK 0 mil in 2017

By Helgi Library - April 2, 2020

Novartis Czech Republic's total assets reached CZK 1,898 mil at the end of 2017, up 9.89% compared to the previous year. ...

Novartis Czech Republic's Cash & Cash Equivalents fell 100% yoy to CZK 0 mil in 2017

By Helgi Library - April 2, 2020

Novartis Czech Republic's total assets reached CZK 1,898 mil at the end of 2017, up 9.89% compared to the previous year. ...

Summary
Financials
Reports
Charts
News
About

Annual Quarterly

Profit Statement		2015	2016	2017
Sales	CZK mil	5,393	6,392	6,312
Gross Profit	CZK mil	776	1,182	1,559
EBITDA	CZK mil	131	170	138
EBIT	CZK mil	111	148	111
Financing Cost	CZK mil	5.81	5.38	5.50
Pre-Tax Profit	CZK mil	105	142	105
Net Profit	CZK mil	82.7	75.6	71.0
Dividends	CZK mil	0	0	0

Balance Sheet		2015	2016	2017
Total Assets	CZK mil	1,911	1,727	1,898
Non-Current Assets	CZK mil	55.3	136	126
Current Assets	CZK mil	1,853	1,588	1,770
Working Capital	CZK mil	951	1,001	1,242
Shareholders' Equity	CZK mil	505	581	652
Liabilities	CZK mil	1,406	1,146	1,246
Total Debt	CZK mil	0	19.2	51.2
Net Debt	CZK mil	-1.97	18.0	51.2

Ratios		2015	2016	2017
ROE	%	17.8	13.9	11.5
ROCE	%	8.58	7.05	5.67
Gross Margin	%	14.4	18.5	24.7
EBITDA Margin	%	2.42	2.66	2.18
EBIT Margin	%	2.05	2.31	1.76
Net Margin	%	1.53	1.18	1.12
Net Debt/EBITDA		-0.015	0.106	0.371
Net Debt/Equity	%	-0.390	3.10	7.85
Cost of Financing	%	12.1	56.0	15.6

Cash Flow		2015	2016	2017
Total Cash From Operations	CZK mil	155	64.0	-16.5
Total Cash From Investing	CZK mil	-41.3	-103	-16.7
Total Cash From Financing	CZK mil	0	0	0
Net Change In Cash	CZK mil	114	-38.6	-33.2
Cash Conversion Cycle	days	66.1	61.2	79.3
Cash Earnings	CZK mil	102	97.9	98.1
Free Cash Flow	CZK mil	114	-38.6	-33.2

Get all company financials in excel:

Download Sample $19.99

summary
income statement
balance sheet
cash flow
other data

summary	Unit	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
income statement
Sales	CZK mil												3,962	3,930	4,056	4,686	5,393
Gross Profit	CZK mil												405	435	500	710	776
EBIT	CZK mil												56.7	64.0	62.4	97.6	111
Net Profit	CZK mil												41.7	50.0	52.3	82.2	82.7
ROE	%												19.2	18.9	16.5	21.6	17.8
EBIT Margin	%												1.43	1.63	1.54	2.08	2.05
Net Margin	%												1.05	1.27	1.29	1.75	1.53
Employees													248	255	267	276	327
balance sheet
Total Assets	CZK mil												1,401	1,514	1,507	1,646	1,911
Non-Current Assets	CZK mil												12.0	23.4	34.3	34.3	55.3
Current Assets	CZK mil												1,383	1,487	1,469	1,611	1,853
Shareholders' Equity	CZK mil												238	292	340	423	505
Liabilities	CZK mil												1,163	1,222	1,167	1,224	1,406
Non-Current Liabilities	CZK mil												0	0	0	0	0
Current Liabilities	CZK mil												1,154	1,205	1,147	1,203	1,380
Net Debt/EBITDA													3.22	0.696	-0.064	0.826	-0.015
Net Debt/Equity	%												83.3	16.7	-1.34	22.0	-0.390
Cost of Financing	%	...											2.97	10.8	36.9	17.3	12.1
cash flow
Total Cash From Operations	CZK mil												-113	167	80.7	90.3	155
Total Cash From Investing	CZK mil												-2.94	-17.3	-19.9	-15.1	-41.3
Total Cash From Financing	CZK mil												0	0	0	0	0
Net Change In Cash	CZK mil												-116	150	60.8	75.2	114

income statement	Unit	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
income statement
Sales	CZK mil												3,962	3,930	4,056	4,686	5,393
Cost of Goods & Services	CZK mil												3,557	3,496	3,556	3,976	4,616
Gross Profit	CZK mil												405	435	500	710	776
Staff Cost	CZK mil												310	336	402	569	616
Other Cost	CZK mil												33.0	28.5	27.3	28.0	29.8
EBITDA	CZK mil												61.6	69.8	71.6	113	131
Depreciation	CZK mil												4.96	5.86	9.18	15.3	19.8
EBIT	CZK mil												56.7	64.0	62.4	97.6	111
Financing Cost	CZK mil												5.49	14.0	10.2	8.33	5.81
Extraordinary Cost	CZK mil												0	0	0	0	0
Pre-Tax Profit	CZK mil												51.2	50.0	52.3	89.2	105
Tax	CZK mil												9.43	-4.07	3.93	7.01	22.3
Minorities	CZK mil												0	0	0	0	0
Net Profit	CZK mil												41.7	50.0	52.3	82.2	82.7
Dividends	CZK mil												0	0	0	0	0
growth rates
Total Revenue Growth	%	...											4.72	-0.791	3.20	15.5	15.1
Operating Cost Growth	%	...											8.43	6.24	17.6	39.1	8.21
EBITDA Growth	%	...											3.11	13.4	2.54	57.5	15.7
EBIT Growth	%	...											1.78	12.9	-2.41	56.3	13.5
Pre-Tax Profit Growth	%	...											-1.98	-2.34	4.60	70.8	17.6
Net Profit Growth	%	...											0.860	19.7	4.60	57.3	0.548
ratios
ROE	%												19.2	18.9	16.5	21.6	17.8
ROCE	%	...											7.85	8.64	5.36	7.06	8.58
Gross Margin	%												10.2	11.1	12.3	15.1	14.4
EBITDA Margin	%												1.56	1.78	1.77	2.41	2.42
EBIT Margin	%												1.43	1.63	1.54	2.08	2.05
Net Margin	%												1.05	1.27	1.29	1.75	1.53
Payout Ratio	%												0	0	0	0	0
Cost of Financing	%	...											2.97	10.8	36.9	17.3	12.1
Net Debt/EBITDA													3.22	0.696	-0.064	0.826	-0.015

balance sheet	Unit	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
balance sheet
Non-Current Assets	CZK mil												12.0	23.4	34.3	34.3	55.3
Property, Plant & Equipment	CZK mil												12.0	23.4	34.3	34.3	55.3
Intangible Assets	CZK mil												0	0	0	0	0.708
Current Assets	CZK mil												1,383	1,487	1,469	1,611	1,853
Inventories	CZK mil												787	723	846	865	1,051
Receivables	CZK mil												590	757	1,459	743	799
Cash & Cash Equivalents	CZK mil												6.37	6.57	4.57	2.88	1.97
Total Assets	CZK mil												1,401	1,514	1,507	1,646	1,911
Shareholders' Equity	CZK mil												238	292	340	423	505
Of Which Minority Interest	CZK mil												0	0	0	0	0
Liabilities	CZK mil												1,163	1,222	1,167	1,224	1,406
Non-Current Liabilities	CZK mil												0	0	0	0	0
Long-Term Debt	CZK mil												0	0	0	0	0
Deferred Tax Liabilities	CZK mil												0	0	0	0	0
Current Liabilities	CZK mil												1,154	1,205	1,147	1,203	1,380
Short-Term Debt	CZK mil												205	55.2	0	96.0	0
Trade Payables	CZK mil												773	963	931	722	899
Provisions	CZK mil												8.56	11.9	13.4	18.6	25.9
Equity And Liabilities	CZK mil												1,401	1,514	1,507	1,646	1,911
growth rates
Total Asset Growth	%	...											12.2	8.05	-0.432	9.23	16.1
Shareholders' Equity Growth	%	...											21.3	22.7	16.5	24.2	19.6
Net Debt Growth	%	...											141	-75.5	-109	-2,141	-102
Total Debt Growth	%	...					...						24.4	-73.0	-100	...	-100	...
ratios
Total Debt	CZK mil												205	55.2	0	96.0	0
Net Debt	CZK mil												198	48.6	-4.57	93.2	-1.97
Working Capital	CZK mil												604	517	1,375	886	951
Capital Employed	CZK mil												616	540	1,409	921	1,007
Net Debt/Equity	%												83.3	16.7	-1.34	22.0	-0.390
Cost of Financing	%	...											2.97	10.8	36.9	17.3	12.1

cash flow	Unit	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
cash flow
Net Profit	CZK mil												41.7	50.0	52.3	82.2	82.7
Depreciation	CZK mil												4.96	5.86	9.18	15.3	19.8
Non-Cash Items	CZK mil	...											11.5	23.5	877	-495	117
Change in Working Capital	CZK mil	...											-172	87.7	-858	488	-64.9
Total Cash From Operations	CZK mil												-113	167	80.7	90.3	155
Capital Expenditures	CZK mil												-3.06	-17.3	-20.2	-15.3	-41.6
Other Investments	CZK mil												0.121	0.025	0.280	0.225	0.306
Total Cash From Investing	CZK mil												-2.94	-17.3	-19.9	-15.1	-41.3
Dividends Paid	CZK mil												0	0	0	0	0
Issuance Of Shares	CZK mil												0	0	0	0	0
Issuance Of Debt	CZK mil	...											40.2	-150	-55.2	96.0	-96.0
Total Cash From Financing	CZK mil												0	0	0	0	0
Net Change In Cash	CZK mil												-116	150	60.8	75.2	114
ratios
Days Sales Outstanding	days												54.4	70.3	131	57.9	54.1
Days Sales Of Inventory	days												80.7	75.5	86.9	79.4	83.1
Days Payable Outstanding	days												79.3	101	95.5	66.3	71.1
Cash Conversion Cycle	days												55.8	45.2	123	71.0	66.1
Cash Earnings	CZK mil												46.7	55.8	61.4	97.5	102
Free Cash Flow	CZK mil												-116	150	60.8	75.2	114

other data	Unit	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
other data
ROA	%												3.15	3.43	3.46	5.22	4.65
Gross Margin	%												10.2	11.1	12.3	15.1	14.4
Employees													248	255	267	276	327
Cost Per Employee	USD per month												5,894	5,617	6,405	8,034	6,576
Cost Per Employee (Local Currency)	CZK per month												104,246	109,862	125,322	171,709	156,955
Staff Cost (As % Of Total Cost)	%												7.94	8.70	10.1	12.4	11.7
Effective Tax Rate	%												18.4	-8.15	7.52	7.86	21.2
Domestic Sales	CZK mil	...	...	...	...	...	...	...	...	...	...	...	...	...	...	3,035	3,486
Capital Expenditures (As % of Sales)	%												0.077	0.440	0.497	0.327	0.771
Revenues From Abroad	CZK mil	...	...	...	...	...	...	...	...	...	...	...	...	...	...	1,651	1,906
Revenues From Abroad (As % Of Total)	%	...	...	...	...	...	...	...	...	...	...	...	...	...	...	35.2	35.3

Get all company financials in excel:

Download Sample $19.99

Comparison of 9 Companies in Czech Pharmaceutical Companies
Annual Data (2000 - 2017)

Nov 2018

Statistical Dossier

$179.99

Novartis Czech Republic in Numbers
Annual (2000 - 2017)

Nov 2018

Statistical Dossier

$19.99

Finance

Novartis Czech Republic has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 14.6% a year during that time to total of CZK 138 mil in 2017, or 2.18% of sales. That’s compared to 2.29% average margin seen in last five years.

The company netted CZK 71.0 mil in 2017 implying ROE of 11.5% and ROCE of 5.67%. Again, the average figures were 16.3% and 6.74%, respectively when looking at the previous 5 years.

Novartis Czech Republic’s net debt amounted to CZK 51.2 mil at the end of 2017, or 7.85% of equity. When compared to EBITDA, net debt was 0.371x, up when compared to average of 0.245x seen in the last 5 years.

More Companies in Czech Pharmaceutical Sector

Amgen Czech Republic
Bayer Czech Republic
GlaxoSmithKline Czech Republic
Merck Czech Republic
Pfizer Czech Republic
Roche Czech Republic
Sanofi-Aventis Czech Republic
Servier Czech Republic
Walmark

Institutional Sign In

Novartis Czech Republic

Novartis Czech Republic's Cash & Cash Equivalents fell 100% yoy to CZK 0 mil in 2017

Novartis Czech Republic's Cash & Cash Equivalents fell 100% yoy to CZK 0 mil in 2017

What Banking Operates with most of its Own Capital?

Bank Equity (As % of Bank Assets) rose 1.48% to 7.35% in Guatemala in 2024

What Banking Has a Problem with Bad Loans?

FX Rate to USD (Average) rose 4.89% yoy to 1.59 per USD in Australia in 1Q2025

FX Rate to USD (Average) rose 4.37% yoy to 86.7 per USD in Bhutan in 1Q2025

FX Rate to USD (Average) rose 10.2% yoy to 121 per USD in Bangladesh in 1Q2025

FX Rate to USD (Average) rose 3.15% yoy to 1.86 per USD in Bulgaria in 1Q2025

FX Rate to USD (Average) rose 0.628% yoy to 1.35 per USD in Brunei in 1Q2025

FX Rate to USD (Average) fell 1.24% yoy to 7.71 per USD in Guatemala in 1Q2025

Finance

More Companies in Czech Pharmaceutical Sector